Literature DB >> 16240058

Vascular morphogenesis in the primate ovary.

Hamish M Fraser1, W Colin Duncan.   

Abstract

Ovarian function is dependent on intense cyclical vascular morphogenesis and regression. The molecular and cellular pathways involved in the generation of new capillary networks in the ovary are now being elucidated. Focussing on the marmoset, the course of angiogenesis at different stages of follicular maturation and in the corpus luteum throughout the cycle and in early pregnancy have been quantified and major progress has been made in the evaluation of the role of vascular endothelial growth factor (VEGF). To study the physiological role of VEGF in follicular and luteal angiogenesis in detail, VEGF was inhibited during defined stages of the cycle in vivo. VEGF antagonist administered throughout the follicular phase of the cycle resulted in a marked decrease in endothelial cell proliferation in developing antral follicles, accompanied by a decline in granulosa cell proliferation, restriction of follicular growth and inhibition of ovulation. An outstanding feature in the ovary is the intense angiogenesis that occurs during the early luteal phase. VEGF inhibitors markedly suppressed this angiogenesis, resulting in a marked restriction in the development of the microvascular tree and suppression of plasma progesterone. These studies showed that VEGF is essential for normal follicular and luteal angiogenesis and function, and demonstrated how luteal angiogenesis in particular could serve as a sensitive bioassay for putative angiogenic antagonists. Antagonists of VEGF are potent tools for investigating the role of angiogenic factors within the ovary and may have applications to the treatment of reproductive disorders characterised by alterations in normal vascular structure or function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16240058     DOI: 10.1007/s10456-005-9004-y

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   9.596


  18 in total

1.  Matrix metalloproteinases -2 and -9 in swine luteal tissue angiogenesis and angioregression.

Authors:  L A Ribeiro; M E Turba; C Bernardini; A Zannoni; M L Bacci; M Forni
Journal:  Vet Res Commun       Date:  2007-08       Impact factor: 2.459

Review 2.  Angiogenesis in the human corpus luteum.

Authors:  Norihiro Sugino; Aki Matsuoka; Ken Taniguchi; Hiroshi Tamura
Journal:  Reprod Med Biol       Date:  2008-04-17

3.  Rapid remodeling of airway vascular architecture at birth.

Authors:  Amy Ni; Erin Lashnits; Li-Chin Yao; Peter Baluk; Donald M McDonald
Journal:  Dev Dyn       Date:  2010-09       Impact factor: 3.780

Review 4.  Understanding vascular development.

Authors:  Ryan S Udan; James C Culver; Mary E Dickinson
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2012-10-05       Impact factor: 5.814

5.  Placental Growth Factor Is Required for Ovulation, Luteinization, and Angiogenesis in Primate Ovulatory Follicles.

Authors:  Hannah R Bender; Heidi A Trau; Diane M Duffy
Journal:  Endocrinology       Date:  2018-02-01       Impact factor: 4.736

6.  TGFB1 disrupts the angiogenic potential of microvascular endothelial cells of the corpus luteum.

Authors:  Dulce Maroni; John S Davis
Journal:  J Cell Sci       Date:  2011-06-21       Impact factor: 5.285

7.  Prostaglandin E2 and vascular endothelial growth factor A mediate angiogenesis of human ovarian follicular endothelial cells.

Authors:  Heidi A Trau; Mats Brännström; Thomas E Curry; Diane M Duffy
Journal:  Hum Reprod       Date:  2016-01-05       Impact factor: 6.918

8.  Changes in circulating levels and ratios of angiopoietins during pregnancy but not during the menstrual cycle and controlled ovarian stimulation.

Authors:  Amanda K Hurliman; Leon Speroff; Richard L Stouffer; Phillip E Patton; Annette Lee; Theodore A Molskness
Journal:  Fertil Steril       Date:  2009-05-23       Impact factor: 7.329

9.  A review on angiogenesis and its assays.

Authors:  Zoya Tahergorabi; Majid Khazaei
Journal:  Iran J Basic Med Sci       Date:  2012-11       Impact factor: 2.699

10.  Ovarian cancer: emerging molecular-targeted therapies.

Authors:  Carole Sourbier
Journal:  Biologics       Date:  2012-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.